Logo Image
|Videos|June 16, 2017

Can New Antimalarials Be a Gamechanger in Endemic Countries?

Jeremy Burrows, DPhil, MA, explains how new antimalarials could change the game for countries where malaria is endemic.

Jeremy Burrows, DPhil, MA, Vice President, Head of Discovery, Medicines for Malaria Venture, Switzerland, explains how new antimalarials could change the game for countries where malaria is endemic.

Interview Transcript (slightly modified for readability)

“In the countries where malaria is endemic, these new treatment options are still incredibly important. First, because they will provide the treatment options of the future when the existing drugs fail because of resistance. Secondly, we have this ambition for elimination, eradication, and these new drugs, which are coming through the pipeline we hope will deliver the tools that will actually enable us to do that.”

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more